Click it and Unblock the Notifications
Just In
Don't Miss
-
Looking forward to 2021: Indian Hockey team captains aim nothing short of a medal at Tokyo Olympics -
Genelia Deshmukh Slays Her Red And Blue Dress In The Sassiest Way And You Must Take Some Styling Tips From Her -
Xiaomi Mi 11 Pro Might Feature Same Display As Mi 11 -
LPG Cylinder Prices Hiked For Commercial Consumers -
Tribhanga Teaser: Kajol, Tanvi Azmi And Mithila Palkar's Netflix Film To Release On January 15 -
Car Sales Report For December 2020: MG Motor India Registers 33 Percent Growth In Yearly Sales -
HP TET Answer Key 2020 Released For November Session -
10 Best Places To Visit In India In January 2021
CDSCO expert panel recommends approval of Oxford COVID-19 vaccine Covishield for emergency use in India
New Delhi, Jan 01: The subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) expert panel on Friday recommended approval of Oxford COVID-19 vaccine Covishield for emergency use in India.
The Pune-based Serum Institute of India (SII), the world''s largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.
The UK''s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday had approved the COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use.
The Subject Expert Committee (SEC) on COVID-19 of the CDSCO, which had earlier sought additional safety and immunogenicity data from SII, deliberated on its application seeking emergency use authorisation (EUA) for the shots on Wednesday, and met again on Friday to review the matter.
After SII''s application, the SEC has started reviewing the EUA application by Bharat Biotech for its COVID-19 vaccine Covaxin but is yet to take a final decision on the matter, sources said.
Govt allows import, export of Covid-19 vaccine without any value limitation
"In terms of safety, Covishield was well tolerated with respect to solicited adverse events...majority of solicited reactions were mild in severity and resolved without any sequelae.
"Therefore, Covishield is safe and can be used effectively for prevention of COVID-19 in the targeted population. Thus, the benefit to risk ratio strongly supports the widespread use of Covishield," the EUA application signed by Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs at Serum Institute of India (SII), had stated.
SII had applied to the Drugs Controller General of India (DCGI) for EUA for Oxford COVID-19 vaccine on December 6, while the Hyderabad-based Bharat Biotech had sought the nod for its indigenously developed Covaxin on December 7.
Pfizer had applied for regulatory approval for its vaccine on December 4.
